Display options
Cite
Li J, Chen Y, Jin M, et al. MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1. Oncol Lett. 2017;13(3):1451-1455doi: 10.3892/ol.2017.5574.
Li, J., Chen, Y., Jin, M., Wang, J., Li, S., Chen, Z., & Yu, W. (2017). MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1. Oncology letters, 13(3), 1451-1455. https://doi.org/10.3892/ol.2017.5574
Li, Jipeng, et al. "MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1." Oncology letters vol. 13,3 (2017): 1451-1455. doi: https://doi.org/10.3892/ol.2017.5574
Li J, Chen Y, Jin M, Wang J, Li S, Chen Z, Yu W. MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1. Oncol Lett. 2017 Mar;13(3):1451-1455. doi: 10.3892/ol.2017.5574. Epub 2017 Jan 05. PMID: 28454276; PMCID: PMC5403496.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Mar;13(3):1451-1455. doi: 10.3892/ol.2017.5574. Epub 2017 Jan 05.

MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1.

Oncology letters

Jipeng Li, Ying Chen, Mingwei Jin, Jianhua Wang, Shanfeng Li, Zhe Chen, Wanjun Yu

Affiliations

  1. Department of Central Laboratory, Yinzhou People's Hospital, Ningbo, Zhejiang 315040, P.R. China.
  2. Department of Respiratory and Critical Care Medicine, Yinzhou People's Hospital, Ningbo, Zhejiang 315040, P.R. China.

PMID: 28454276 PMCID: PMC5403496 DOI: 10.3892/ol.2017.5574

Abstract

Multidrug resistance (MDR) is the primary barrier to the success of chemotherapy for lung adenocarcinoma. MicroRNA (miR)-134, which is downregulated in lung adenocarcinoma, influences cell proliferation, apoptosis and invasion of lung adenocarcinoma. However, the function of miR-134 in the MDR of lung adenocarcinoma remains unclear. In the present study, it was identified that miR-134 expression is significantly downregulated in A549/cisplatin MDR lung adenocarcinoma cells, as compared with A549 parental cells. miR-134 regulates the sensitivity of lung adenocarcinoma cells to certain anticancer drugs. Furthermore, it was demonstrated that forkhead box M1 and multidrug resistance-associated protein 1 are functional targets of miR-134. These data revealed an important role for miR-134 in the regulation of MDR in lung adenocarcinoma.

Keywords: forkhead box M1; lung adenocarcinoma; microRNA-134; multidrug resistance; multidrug resistance-associated protein 1

References

  1. Nat Rev Drug Discov. 2006 Mar;5(3):219-34 - PubMed
  2. Proc Natl Acad Sci U S A. 2013 Jun 4;110(23 ):9249-54 - PubMed
  3. Mol Cancer. 2014 Aug 16;13:193 - PubMed
  4. Oncotarget. 2015 Feb 10;6(4):2349-65 - PubMed
  5. Methods. 2001 Dec;25(4):402-8 - PubMed
  6. Respir Res. 2013 Jun 03;14:63 - PubMed
  7. Mol Carcinog. 2013 Jan;52(1):70-8 - PubMed
  8. Drug Metab Rev. 2015 ;47(4):406-19 - PubMed
  9. Clin Cancer Res. 2001 Jun;7(6):1798-804 - PubMed
  10. Mol Cancer Res. 2010 Jan;8(1):24-34 - PubMed
  11. Mol Cancer. 2014 Jan 03;13:1 - PubMed
  12. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  13. FEBS Lett. 2012 Oct 19;586(20):3761-5 - PubMed
  14. Clin Lung Cancer. 2009 Nov;10 (6):414-21 - PubMed
  15. FEBS Lett. 2015 Jan 16;589(2):207-14 - PubMed
  16. Oncogene. 2007 Sep 13;26(42):6212-9 - PubMed
  17. Int J Nanomedicine. 2013;8:1867-77 - PubMed
  18. Cancer Res. 2013 Jan 15;73(2):473-7 - PubMed
  19. Mol Cell Biol. 2007 Feb;27(3):1007-16 - PubMed
  20. Biochem J. 2012 Sep 1;446(2):291-300 - PubMed
  21. Oncotarget. 2015 Feb 20;6(5):3147-64 - PubMed
  22. Nat Rev Cancer. 2002 Jan;2(1):48-58 - PubMed
  23. Cell Death Dis. 2015 May 21;6:e1766 - PubMed
  24. Cancer Treat Rev. 2010 Apr;36(2):151-6 - PubMed
  25. Int J Cancer. 2005 Feb 10;113(4):568-74 - PubMed
  26. Cell Death Differ. 2014 May;21(5):720-34 - PubMed
  27. Oncotarget. 2016 Jun 14;7(24):35960-35978 - PubMed

Publication Types